4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa, choroideremia, and 4 D-310.
Market Cap | 610.847 Million | Shares Outstanding | 33.234 Million | Avg 30-day Volume | 625.119 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.79 |
Price to Revenue | 254.7634 | Debt to Equity | 0.0 | EBITDA | -109.162 Million |
Price to Book Value | 2.5732 | Operating Margin | -5151.5399 | Enterprise Value | 360.658 Million |
Current Ratio | 18.358 | EPS Growth | -0.216 | Quick Ratio | 17.774 |
1 Yr BETA | 1.2107 | 52-week High/Low | 26.49 / 5.32 | Profit Margin | -4974.5471 |
Operating Cash Flow Growth | -17.7579 | Altman Z-Score | 10.7445 | Free Cash Flow to Firm | -70.046 Million |
Earnings Report | 2023-08-10 |
Please sign in first
850 Thousand total shares from 1 transactions
8.8 Thousand total shares from 2 transactions
11.8 Thousand total shares from 3 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2023-05-23 | 1 | |
|
0 | 2023-05-23 | 2 | |
|
0 | 2023-05-23 | 1 | |
|
0 | 2023-05-23 | 1 | |
|
0 | 2023-05-23 | 1 | |
|
0 | 2023-05-23 | 1 | |
|
0 | 2023-05-23 | 3 | |
MORETTI AUGUST J CHIEF FINANCIAL OFFICER |
|
11,045 | 2023-05-15 | 4 |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC VIKING GLOBAL OPPORTUNITIES GP LLC |
|
4,787,914 | 2023-05-09 | 1 |
KIRN DAVID CHIEF EXECUTIVE OFFICER |
|
1,859,153 | 2023-05-02 | 5 |
BIZILY SCOTT CHIEF LEGAL AND HR OFFICER |
|
2,109 | 2023-04-21 | 6 |
KIM ROBERT YOUNG CHIEF MEDICAL OFFICER |
|
0 | 2023-03-24 | 1 |
KAMAL FARIBORZ PRESIDENT & COO |
|
0 | 2023-02-10 | 3 |
FISHMAN ROBERT S CHIEF MEDICAL OFFICER |
|
60,000 | 2022-09-01 | 1 |
BIOTECHNOLOGY VALUE FUND II LP |
|
3,912,984 | 2022-06-16 | 1 |
ZIMMERMANN CAROLYNE CHIEF BUSINESS OFFICER |
|
35,000 | 2022-02-01 | 0 |
|
901,215 | 2021-10-20 | 0 | |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
3,937,914 | 2020-12-15 | 0 |
|
1,063,744 | 2020-12-15 | 0 | |
|
0 | 2020-12-10 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-05-25 19:42:12 -0400 | 2023-05-23 | A | 33,750 | a | 33,750 | direct | ||||||||||
2023-05-25 19:39:14 -0400 | 2023-05-23 | A | 22,500 | a | 22,500 | direct | ||||||||||
2023-05-25 19:37:06 -0400 | 2023-05-23 | A | 22,500 | a | 22,500 | direct | ||||||||||
2023-05-25 19:35:36 -0400 | 2023-05-23 | A | 22,500 | a | 22,500 | direct | ||||||||||
2023-05-25 19:33:54 -0400 | 2023-05-23 | A | 22,500 | a | 22,500 | direct | ||||||||||
2023-05-25 19:32:17 -0400 | 2023-05-23 | A | 22,500 | a | 22,500 | direct | ||||||||||
2023-05-25 19:31:19 -0400 | 2023-05-23 | A | 22,500 | a | 22,500 | direct | ||||||||||
2023-05-16 20:52:00 -0400 | 2023-05-15 | M | 3,000 | $9.41 | a | 11,045 | direct | -3.0253 | -0.7151 | 0.8251 | 4 | -3.0253 | 2 | |||
2023-05-16 20:52:00 -0400 | 2023-05-15 | M | 3,000 | d | 217,060 | direct | ||||||||||
VIKING GLOBAL INVESTORS LP - > 10% Owner see explanation responses VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP - > 10% Owner see explanation responses VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC - > 10% Owner see explanation responses VIKING GLOBAL OPPORTUNITIES GP LLC - > 10% Owner see explanation responses VIKING GLOBAL OPPORTUNITIES PARENT GP LLC - > 10% Owner see explanation responses HALVORSEN OLE ANDREAS - > 10% Owner see explanation responses OTT DAVID C. - > 10% Owner see explanation responses SHABET ROSE SHARON - > 10% Owner see explanation responses |
2023-05-11 17:50:40 -0400 | 2023-05-09 | P | 850,000 | $16.00 | a | 4,787,914 | indirect | -0.5025 | 0.7817 | 1.5075 | 4 | -1.5634 | 5 | ||
2023-05-04 20:09:22 -0400 | 2023-05-02 | G | 600,000 | d | 1,259,153 | direct | -2.4793 | 5.7261 | 5.7261 | 6 | -2.4793 | 2 | ||||
KIRN DAVID - Director - Officer CHIEF EXECUTIVE OFFICER family trusts |
2023-05-04 20:09:22 -0400 | 2023-05-02 | G | 600,000 | a | 600,000 | indirect | -2.4793 | 5.7261 | 5.7261 | 6 | -2.4793 | 2 | |||
2023-04-25 18:43:09 -0400 | 2023-04-21 | M | 5,000 | $9.41 | a | 5,000 | direct | yes | -19.7861 | -7.5352 | 0.0 | 1 | -19.7861 | 2 | ||
2023-04-25 18:44:59 -0400 | 2023-04-21 | M | 3,750 | d | 52,500 | direct | yes | |||||||||
2023-04-25 18:44:59 -0400 | 2023-04-21 | S | 3,750 | $20.00 | d | 2,109 | direct | yes | -19.7861 | -7.5352 | 0.0 | 1 | -19.7861 | 2 | ||
2023-04-25 18:44:59 -0400 | 2023-04-21 | M | 3,750 | $8.04 | a | 5,859 | direct | yes | -19.7861 | -7.5352 | 0.0 | 1 | -19.7861 | 2 | ||
2023-04-25 18:43:09 -0400 | 2023-04-21 | M | 5,000 | d | 32,500 | direct | yes | |||||||||
2023-04-25 18:43:09 -0400 | 2023-04-21 | S | 5,000 | $20.05 | d | 0 | direct | yes | -19.7861 | -7.5352 | 0.0 | 1 | -19.7861 | 2 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 22:15:04 UTC | 4.6194 | 0.4406 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 21:45:04 UTC | 4.6194 | 0.4406 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 21:15:03 UTC | 4.6194 | 0.4406 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 20:45:04 UTC | 4.6194 | 0.4406 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 20:15:06 UTC | 4.6194 | 0.4406 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 19:45:04 UTC | 4.6194 | 0.4406 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 19:15:21 UTC | 4.5869 | 0.4731 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 18:45:03 UTC | 4.5869 | 0.4731 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 18:15:04 UTC | 4.5869 | 0.4731 | 400000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 17:45:03 UTC | 4.5869 | 0.4731 | 400000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 17:15:05 UTC | 4.5869 | 0.4731 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 16:45:04 UTC | 4.8008 | 0.2692 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 16:15:04 UTC | 4.8008 | 0.2692 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 15:45:03 UTC | 4.8008 | 0.2692 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 15:15:04 UTC | 4.8008 | 0.2692 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 14:45:04 UTC | 4.8008 | 0.2692 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 14:15:03 UTC | 4.8008 | 0.2692 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 13:45:04 UTC | 4.8092 | 0.2608 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 13:15:04 UTC | 4.8092 | 0.2608 | 500000 |
4D MOLECULAR THERAPEUTICS IN FDMT | 2023-05-31 12:45:04 UTC | 4.8092 | 0.2608 | 500000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|